Invasive rhino-orbito-cerebral mucormycosis in a diabetic patient – the need for prompt treatment

@inproceedings{Chow2015InvasiveRM,
  title={Invasive rhino-orbito-cerebral mucormycosis in a diabetic patient – the need for prompt treatment},
  author={Vanessa Chow and Sheema Khan and Adeola Fatima Balogun and David L. Mitchell and Fritz A. M{\"u}hlschlegel},
  booktitle={Medical mycology case reports},
  year={2015}
}
Mucormycosis is a rare life threatening fungal infection predominately seen in immunocompromised or diabetic patients. The following case is of a known type II diabetic patient who presented with sepsis and sudden unilateral loss of vision secondary to infective rhino-orbito-cerebral mucormycosis. Treatment of the condition required extensive surgical intervention and medical management for a life saving outcome. 

References

Publications referenced by this paper.
SHOWING 1-10 OF 19 REFERENCES

J

  • B. Spellberg, A. S. Ibrahim, P. V. Chin-Hong, D. P. Kontoyiannis, M. I. Morris
  • R. Perfect, et al., The Deferasirox-Am-Bisome therapy for mucormycosis (DE- FEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial, J. Antimicrob. Chemother. 67
  • 2012
VIEW 11 EXCERPTS
HIGHLY INFLUENTIAL

A

  • O. A. Cornely, S. Arikan-Akdagli, E. Dannaoui, A. H. Groll, K. Lagrou
  • Chakrabarti, et al., ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis, Clin. Microbiol. Infect. 20 (3)
  • 2014

ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013.

Epidemiology and clinical manifestations of mucormycosis.

VIEW 2 EXCERPTS

Rhinocerebral Mucormycosis [Internet

  • M. T. Yen, W. P. Baugh
  • [Place unknown]: Medline
  • 2011
VIEW 2 EXCERPTS

F

  • D. Bitar, D. Van Cauteren, F. Lanternier, E. Dannaoui, D. Che
  • Dromer, et al., Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006, Emerg. Infect. Dis. 15
  • 2009
VIEW 2 EXCERPTS

H

  • B. Spellberg, D. Andes, M. Perez, A. Anglim
  • Bonilla, G.E. Mathisen, et al., Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis, Antimicrob. Agents Chemother. 53
  • 2009
VIEW 1 EXCERPT